R&D Trends

AZ, BioFocus, Argenta collaborate on respiratory and inflammatory diseases

Thursday, March 15, 2012 06:02 AM

Galapagos’ service companies, BioFocus and Argenta, have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets in respiratory and inflammatory diseases.

More... »

IMI creates platform to discover novel medicines

Monday, March 12, 2012 02:04 PM

In an effort to speed up the discovery of new medicines, the Innovative Medicines Initiative (IMI) has created the European Lead Factory, a Europe-wide public-private partnership that combines the Joint European Compound Collection, a comprehensive collection of candidate drug molecules, with an industry-like screening center.

More... »

FutureCeuticals opens bioclinical research facility

Monday, March 12, 2012 02:01 PM

FutureCeuticals, an R&D and manufacturing company of fruit, vegetable and grain-based products for the functional food and dietary supplement markets, has opened Applied BioClinical (ABC), a new bioclinical research facility in Irvine, Calif.

More... »

Sanofi to collaborate with the Center for Genomic Regulation

Friday, March 9, 2012 02:21 PM

The Center for Genomic Regulation (CRG), an international biomedical research institute of excellence supported by the Catalan government and the Spanish Ministry of Science and Innovation, has entered a research collaboration with Sanofi to share research programs using state-of-the-art experimental platforms and computational and bioinformatics approaches, in computational biology, medical genetics and epigenetics, with special emphasis in genetic and rare diseases.

More... »

IOM report identifies ways to further improve pediatric studies

Friday, March 2, 2012 03:07 PM

Federal laws that motivate or require drug and biologic developers to conduct pediatric studies have yielded beneficial information to guide the use of medications in children, according to a new report by the Institute of Medicine (IOM).  Still, studies involving children continue to be limited, especially in certain areas such as medication use in newborns and long-term safety and effectiveness in children. 

More... »

Celerion and Ricerca Biosciences form The Biosimilars Alliance

Thursday, March 1, 2012 11:23 AM

Lincoln, Neb.-based Celerion, a provider of early-stage drug development solutions, and Ricerca Biosciences, which offer discovery, preclinical and development services, have formed “The Biosimilars Alliance,” focused on preclinical and early clinical assessment of biologics manufactured by a new supplier.

More... »

Lilly introduces global 'Innovation Starts Here' initiative

Thursday, March 1, 2012 06:02 AM

Eli Lilly has launched a global Innovation Starts Here initiative, which supports Lilly's commitment to speeding the delivery of innovative new medicines to patients around the world.

More... »

U.K. unemployment: the case for optimism

Thursday, March 1, 2012 06:01 AM

Dr. John Philpott, chief economic adviser at the Chartered Institute of Personnel and Development (CIPD), told the Yorkshire HR Directors Forum in Leeds on February 29 that even a relatively modest economic recovery in 2012 could see U.K. unemployment stabilize at around the current rate of 8.4%, while a stronger recovery has the potential to result in a sudden sharp fall in the jobless total.

More... »

GlaxoSmithKline and Angiochem collaborate on treatments for LSDs

Thursday, March 1, 2012 05:55 AM

Angiochem, a clinical-stage biotechnology company, has partnered with GlaxoSmithKline (GSK) to discover, develop and commercialize treatments for lysosomal storage diseases (LSDs).

More... »

Shire and arGEN-X enter therapeutic antibody alliance

Wednesday, February 29, 2012 04:12 PM

Netherlands-based arGEN-X has entered into an alliance with U.K.-based Shire Pharmaceuticals to create novel therapeutic antibody products against multiple targets submitted by the latter.

More... »